Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? (2020)
- Authors:
- USP affiliated authors: MELLO, EVANDRO SOBROZA DE - FM ; RIBEIRO JÚNIOR, ULYSSES - FM ; HOFF, PAULO MARCELO GEHM - FM ; CECCONELLO, IVAN - FM
- Unidade: FM
- DOI: 10.1002/jso.25792
- Subjects: ADENOCARCINOMA; ANTÍGENOS; HERPES SIMPLES; ESTUDOS RETROSPECTIVOS; NEOPLASIAS GÁSTRICAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of surgical oncology
- ISSN: 0022-4790
- Volume/Número/Paginação/Ano: v. 121, n. 5, p. 804-813, 2020
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
RAMOS, Marcus F. K. P et al. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?. Journal of surgical oncology, v. 121, n. 5, p. 804-813, 2020Tradução . . Disponível em: https://doi.org/10.1002/jso.25792. Acesso em: 28 dez. 2025. -
APA
Ramos, M. F. K. P., Pereira, M. A., Amorim, L. C., Mello, E. S. de, Faraj, S. F., Ribeiro Junior, U., et al. (2020). Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? Journal of surgical oncology, 121( 5), 804-813. doi:10.1002/jso.25792 -
NLM
Ramos MFKP, Pereira MA, Amorim LC, Mello ES de, Faraj SF, Ribeiro Junior U, Hoff PMG, Cecconello I, Castria TB de. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? [Internet]. Journal of surgical oncology. 2020 ; 121( 5): 804-813.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1002/jso.25792 -
Vancouver
Ramos MFKP, Pereira MA, Amorim LC, Mello ES de, Faraj SF, Ribeiro Junior U, Hoff PMG, Cecconello I, Castria TB de. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? [Internet]. Journal of surgical oncology. 2020 ; 121( 5): 804-813.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1002/jso.25792 - Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer
- Pathologic complete response implies a fewer number of lymph nodes in specimen of rectal cancer patients treated by neoadjuvant therapy and total mesorectal excision
- Lymph node yield after neoadjuvant chemoradiotherapy in rectal cancer specimens: a randomized trial comparing two fixatives
- Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes
- Observation versus surgical resection in patients with rectal cancer who achieved complete clinical response after neoadjuvant chemoradiotherapy: preliminary results of a randomized trial (NCT02052921)
- Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer
- Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei
- Carnoy's solution is an adequate tissue fixative for routine surgical pathology, preserving cell morphology and molecular integrity
- Detection of occult lymph node tumor cells in node-negative gastric cancer patients
- Risk Factors for Lymph Node Metastasis in Western Early Gastric Cancer After Optimal Surgical Treatment
Informações sobre o DOI: 10.1002/jso.25792 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
